Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus

Table 3

Adverse events and hypoglycemic events during the 52-week treatment period.

	No. of patients
SAEs	0
Any AE	5
Upper respiratory tract infection	2
Hypertension	0
Hyperlipidemia	1
Abnormal hepatic function	0
Severe hypoglycemia	0
Clinically significant hypoglycemia (blood glucose level <54 mg·dl^−1)	2

SAE: serious adverse event; AE: adverse event.